Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M.Kopernika W Lodzi

At Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M.Kopernika W Lodzi, a large share of research focuses on hematologic cancers and related blood disorders, especially lymphomas, leukemias, multiple myeloma, and myelodysplastic syndromes. These studies are designed to evaluate new treatment options, compare combination approaches, and improve disease control for patients with relapsed, refractory, or newly diagnosed disease.

• Follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma
• Chronic lymphocytic leukemia, small lymphocytic lymphoma, and chronic myeloid leukemia
• Multiple myeloma, plasma cell myeloma, and light chain amyloidosis
• Myelodysplastic syndromes, myelofibrosis, and polycythemia vera

The site is also involved in trials exploring better ways to manage anemia, immune thrombocytopenia, and autoimmune hemolytic anemia, reflecting a strong interest in improving both cancer care and supportive treatment.

A major research theme at this hospital is the study of solid tumors, with particular attention to non-small cell lung cancer, breast cancer, colorectal cancer, and other advanced cancers. The trials aim to test new therapies, refine treatment sequences, and improve outcomes for patients with locally advanced or metastatic disease.

• Non-small cell lung cancer, including early-stage, locally advanced, and metastatic forms
• Breast cancer, including HER2-positive and hormone receptor-positive disease
• Colorectal cancer, pancreatic ductal adenocarcinoma, and gastroesophageal adenocarcinoma
• Urothelial carcinoma, endometrial cancer, and ovarian cancer

Research here also includes studies in head and neck cancer, melanoma, cervical cancer, and biliary tract cancer, showing a broad oncology portfolio centered on better treatment effectiveness and disease control.

The site participates in studies across cardiovascular disease and heart failure, with work focused on improving symptoms, reducing hospitalizations, and lowering the risk of major heart-related events. These trials are aimed at evaluating new therapies for patients with chronic and high-risk cardiovascular conditions.

• Heart failure, including HFpEF, HFmrEF, and HFrEF
• Atherosclerotic cardiovascular disease and other established cardiovascular conditions
• Hypertension and non-permanent atrial fibrillation
• Cardiovascular risk reduction and prevention of major adverse events

Several studies also address patients with kidney impairment alongside heart disease, highlighting interest in more effective care for complex, multi-morbid cardiovascular populations.

Research at this site extends into respiratory diseases, allergic conditions, and immune-mediated disorders. The trials are generally focused on improving symptom control, reducing flare-ups, and testing new approaches for chronic inflammatory disease.

• Asthma, including moderate-to-severe uncontrolled disease
• Recurrent wheezing and respiratory tract infections in children
• Seasonal allergic rhinitis and rhinoconjunctivitis
• Rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis

The portfolio also includes studies in Sjögren’s disease, idiopathic inflammatory myopathies, and other immune-related conditions, reflecting a broad interest in both respiratory and autoimmune care.

Beyond active cancer treatment, the research program at Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M.Kopernika W Lodzi includes studies on supportive care, infection prevention, and long-term safety. These trials aim to improve quality of life and help patients stay protected during or after treatment.

• Primary immunodeficiency diseases and immune support
• Infection prophylaxis in patients with chronic lymphocytic leukemia
• Long-term follow-up after gene-modified T-cell treatment
• Rollover and continuation studies for patients benefiting from prior therapy

This part of the portfolio shows a clear commitment to monitoring safety over time while helping patients maintain treatment benefit and reduce complications.